血管紧张素转换酶(ACE)抑制剂用于临床已有15年之久,并充分证实是一种有效的能被病人充分耐受的降压药物。新近问世的Trandolapril是一种新型的非巯基口服ACE抑制剂,就其药理作用而言,为一种有原药(Prodrug),首先必须经水解转变为一种有活性的物质-TrandoLapriLat,方能发挥作用。此药具有高度的亲脂性,能很好地穿透到机体各种组织中,尤其是心肌和血管壁。体内外实验均已证实TrandoLepriL不仅具有ACE抑制剂的共同作用,而且能明显地使心肌和动脉壁的病理变化恢复正常。动物实验表明,此药对高血压所致左心室肥厚及平滑肌细胞肥大、胶原基质密度增高、动脉顺应性降低等动脉血管壁结构和功能的异常,均有良好的 Angiotensin converting enzyme (ACE) inhibitors have been used clinically for 15 years and are well documented as effective antihypertensive drugs that are well tolerated by patients. The recently introduced Trandolapril is a novel non-sulfa oral ACE inhibitor that, for its pharmacological effects, is a prodrug that must first be hydrolyzed to an active substance -TrandoLapriLat Play a role. The drug is highly lipophilic and penetrates well into the body’s tissues, especially the myocardium and blood vessel walls. Both in vitro and in vivo experiments have demonstrated that TrandoLepriL not only has the combined effect of an ACE inhibitor, but also significantly regulates the pathological changes in the myocardium and the arterial wall. Animal experiments show that the drug on hypertension caused by left ventricular hypertrophy and smooth muscle cell hypertrophy, increased collagen matrix density, decreased arterial compliance and other arterial wall structure and function abnormalities, have good